FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1137 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR 2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing... June 5, 2022 HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies February 12, 2019 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... March 22, 2023 Load more HOT NEWS What My Mother’s Cancer Diagnosis Taught Me About Supporting a Loved... Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May...
